Rebif® New Formulation (RNF) using RebiSmartTM

Phase	Registry id	Dates	Indication	Sponsor	Status	Outcome
Comparator or background therapy1 trial
Phase 3	NCT00735007 Background	Jul 2008 → Jan 2009	multiple sclerosis	EMD Serono	Completed	No outcome recorded

Date	Issuer	Release
2018-06-14	Merck KGaA, Darmstadt, Germany	Merck to Present Data on Mavenclad® and Rebif® in Relapsing Forms of Multiple Sclerosis at EAN prnewswire.com ↗

Every value below carries the sentence it was read from. 2 sources stand behind the page.

Field	Value	Cited text
Known as	Rebif New Formulation (RNF) using RebiSmartTM	ClinicalTrials.gov intervention name — accepted as the source's own label NCT00735007 ↗
Known as	IFN beta-1a	“subcutaneous (sc) administration of interferon (IFN) beta-1a, 44 mcg three times weekly” PMID 20433746 ↗ Apr 2010
Known as	IFN-β-1a	“The Study Drug - Rebif® New Formulation (RNF) Rebif® is a medicine that is part of a family of proteins called interferon beta-1a (IFN-β-1a) molecules” NCT00735007 ↗
Known as	Rebif	“The Study Drug - Rebif® New Formulation (RNF) Rebif® is a medicine that is part of a family of proteins called interferon beta-1a (IFN-β-1a) molecules” NCT00735007 ↗
Known as	Rebif New Formulation (RNF)	“The Study Drug - Rebif® New Formulation (RNF) Rebif® is a medicine that is part of a family of proteins called interferon beta-1a (IFN-β-1a) molecules” NCT00735007 ↗
Modality	Protein / enzyme biologic	“family of proteins called interferon beta-1a (IFN-β-1a) molecules” NCT00735007 ↗